Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems

Man Ying, Guanyu Chen, Weiyue Lu1

  • 1Department of Pharmaceutics, School of Pharmacy, Fudan University, Zhanghen Road 826 201203, Shanghai, China. wylu@shum.edu.cn.

Insights

Targeted nano-drug delivery systems offer efficient cancer therapy by targeting tumor vasculature. Ligand-modified nanocarriers enhance drug delivery specificity to tumors, improving treatment outcomes.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Targeted nano-drug delivery systems are crucial in cancer therapy.
  • Tumor vasculature, including angiogenesis and vasculogenic mimicry, drives tumor growth and metastasis.
  • Targeting tumor vasculature presents a promising strategy for cancer treatment.

Purpose of the Study:

  • To review tumor vasculature characteristics.
  • To introduce recent advances in nano-drug delivery systems targeting tumor vasculature.
  • To discuss potential strategies for enhanced tumor treatment.

Main Methods:

  • Review of scientific literature on nano-drug delivery and tumor vasculature.
  • Analysis of ligand modification on nanocarriers for active targeting.
  • Description of receptor-ligand interactions for tumor cell and endothelial cell targeting.

Main Results:

  • Nano-drug delivery systems demonstrate efficient drug delivery and tumor site specificity.
  • Ligands on nanocarriers enable active targeting by binding to over-expressed receptors.
  • Targeting tumor vasculature is a viable approach for cancer therapy.

Conclusions:

  • Nano-drug delivery systems targeting tumor vasculature are a promising cancer treatment strategy.
  • Ligand-modified nanocarriers improve targeting efficiency and specificity.
  • Further research into tumor vasculature targeting holds potential for improved cancer therapies.

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
130
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
125
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K